Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial-Reference-Cited by-同舟云学术

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

Published:2022-09 Issue:10357 Volume:400 Page:997-1007
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Shoamanesh Ashkan,Mundl Hardi,Smith Eric E,Masjuan Jaime,Milanov Ivan,Hirano Teruyuki,Agafina Alina,Campbell Bruce,Caso Valeria,Mas Jean-Louis,Dong Qiang,Turcani Peter,Christensen Hanne,Ferro Jose M,Veltkamp Roland,Mikulik Robert,De Marchis Gian Marco,Robinson Thompson,Lemmens Robin,Stepien Adam,Greisenegger Stefan,Roine Risto,Csiba Laszlo,Khatri Pooja,Coutinho Jonathan,Lindgren Arne G,Demchuk Andrew M,Colorado Pablo,Kirsch Bodo,Neumann Christoph,Heenan Laura,Xu Lizhen,Connolly Stuart J,Hart Robert G

Funder

McMaster University

Bayer

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: a guideline from the American Heart Association/American Stroke Association;Kleindorfer;Stroke,2021

2. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack;Wang;N Engl J Med,2013

3. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA;Johnston;N Engl J Med,2018

4. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA;Johnston;N Engl J Med,2020

5. Silent brain infarcts and the risk of dementia and cognitive decline;Vermeer;N Engl J Med,2003

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design;American Heart Journal;2024-11

2. Regulation of Platelet Activation and Coagulation;Interventional Cardiology Clinics;2024-10

3. A pharmacokinetic and pharmacodynamic evaluation of asundexian: a novel factor XIa inhibitor for stroke prevention;Expert Opinion on Drug Metabolism & Toxicology;2024-09-11

4. Laboratory Evaluation of Interferences Associated with Factor XIa Inhibitors Asundexian and Milvexian in Routine Coagulation Assays;Diagnostics;2024-09-09

5. Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation;Expert Opinion on Drug Metabolism & Toxicology;2024-09-02